OSRHW — OSR Holdings, Inc.
NASDAQ · Healthcare · Biotechnology
$0.03
-$0.02 (-44.44%)
OSR Holdings, Inc. (OSRHW) is a biotechnology company listed on NASDAQ. It is led by Kuk Hyoun Hwang, based in 10900 NE 4th Street, Bellevue, WA, United States, 98004, with about 19 employees. OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
Latest reported OSRHW revenue for 2025-09-30 was $627.7K. Net income was -$3.2M.
Use this OSRHW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OSRHW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OSRHW SEC filings page. Lician reads the product cache first so this HTML stays unique to OSR Holdings, Inc. even when a live quote feed is slow.
About OSR Holdings, Inc.
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
OSRHW Key Statistics
Market Cap
$0.00M
Volume
21,163
Previous Close
$0.04
Day Range
$0.03 – $0.03
EPS
-$0.54
Revenue
$0.00
Net Income
-$2.41M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
19
OSRHW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$2.41M | $403.78K | -$35.39K |
| EPS (Diluted) | -$0.54 | $0.05 | -$0.01 |
Total Assets
$2.30M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$66.14K
Operating Cash Flow
-$2.19M
Free Cash Flow
$0.00
OSR Holdings, Inc. Company Information
- Chairman & CEO
- Kuk Hyoun Hwang
- Headquarters
- 10900 NE 4th Street, Bellevue, WA, United States, 98004
- Website
- www.osr-holdings.com
- Phone
- 425-635-7700
- IPO / Founded
- 2023-03-17
- Sector
- Healthcare
- Industry
- Biotechnology